Immunological Complications of Blood Transfusion

Alternatives to Blood Transfusion in Transfusion Medicine: Second Edition

Volumn , Issue , 2010, Pages 31-46

  Taylor, Clare ^a   Navarrete, Cristina ^a   Contreras, Marcela ^b,c  

^a NHS BLOOD AND TRANSPLANT   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c Blood Transfusion International   (United Kingdom)

Author keywords

Allergic and anaphylactic reactions; Clinical signs and symptoms of HTR; Febrile non HTR (FNHTR); Hemolytic transfusion reactions (HTR); Immunological refractoriness to platelet transfusions; Intravenous immunoglobulin (IVIg); Transfusion associated graftversus host disease (TA GVHD); Transfusion related acute lung injury (TRALI)

Indexed keywords

EID: 79960247160     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444319583.ch4     Document Type: Chapter

References (48)

1. Kitchen AD, Barbara AJ. Current information on the infectious risks of allogeneic blood transfusion. In: Maniatis A, Van der Linden P, Hardy J-F (eds). Alternatives to Blood Transfusion in Transfusion Medicine. Wiley-Blackwell, Oxford, 2010, pp. 21-30.
2. Taylor C (Ed.), Cohen H, Mold D, Jones H, et al. on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2008 Annual SHOT Report (2009). Available at: http://www.shotuk.org
3. Stainsby D, Jones H, Asher D, et al. Serious hazards of transfusion: a decade of hemovigilance in the UK. Transfus Med Rev 2006;20:273-82.
4. Sazama K. Reports of 355 transfusion-associated deaths: 1976-1985. Transfusion 1990;30:583-90.
5. Schmidt PJ. The mortality from in compatible transfusion. In: Sandier SG, Nussbacher J, Schanfield MS (eds). Immunobiology of the Erythrocyte. Alan R. Liss, Inc., New York, 1980, pp. 251-61.
6. Walker RH. Noninfectious risks and new trends in transfusion practice. J Fla Med Assoc 1993;80:37-8.
7. Ness PM, Shirey RS, Thoman SK, Buck SA. The differentiation of delayed serologic and delayed hemolytic transfusion reactions: incidence, long-term serologic findings, and clinical significance. Transfusion 1990;30:688-93.
8. Mollison PL, Engelfriet CP, Contreras M. Blood Transfusion in Clinical Medicine, 10th edn. Blackwell Science, Oxford, 1997.
9. Salama A, Mueller-Eckhardt C. Delayed hemolytic transfusion reactions. Evidence for complement activation involving allogeneic and autologous red cells. Transfusion 1984;24:188-93.
10. Vengelen-Tyler V. Technical Manual, 12th edn. American Association of Blood Banks, Bethesda, MD, 1996.
11. Kohan Al, Niborski RC, Rey JA, et al. High-dose intravenous immunoglobulin in non-ABO transfusion incompatibility. Vox Sang 1994;67:195-8.
12. Linden JV, Paul B, Dressier KP. A report of 104 transfusion errors in New York State. Transfusion 1992;32:601-6.
13. National Patient Safety Agency. Right Patient-Right Blood. 2006. Available at: http://npsa.nhs.uk
14. Murphy M, Pamphilon DH. Practical Transfusion Medicine. Blackwell Publishing, Oxford, 2005.
15. Heddle MM, Klama LN, Griffith L, et al. A prospective study to identify the risk factors associated with acute reactions to platelet and red cell transfusions. Transfusion 1993;33:794-7.
16. Payne R. The association of febrile transfusion reactions with leuko-agglutinins. Vox Sang 1957;2:233-41.
17. Dzik WH. Is the febrile response to transfusion due to donor or recipient cytokine? Transfusion 1992;32: 594.
18. Brubaker DB. Clinical significance of white cell antibodies in febrile non-hemolytic transfusion reactions. Transfusion 1990;30:733-7.
19. Heddle NM, Klama L, Singer J, et al. Febrile nonhemolytic transfusion reactions to platelets. Curr Opin Hematol 1995;2:478-83.
20. Heddle N, Tan M, Klama L, Shroeder J. Factors affecting cytokine production in platelet concentrates. Transfusion 1994;34(Suppl.):675 (abstract).
21. Shimizu T, Uchigiri C, Mizuno S, Kamiya T, Kokubo Y. Adsorption of anaphylatoxins and platelet-specific proteins by filtration of platelet concentrates with a polyester leukocyte reduction filter. Vox Sang 1994; 66:161-5.
22. Greenberger PA. Plasma anaphylaxis and immediate type reactions. In: Rossi EC, Simon TL, Moss GS, Gould SA (eds). Principles of Transfusion Medicine, 2nd edn. Williams & Wilkins, Baltimore, 1996, pp. 765-71.
23. Sandier SG, Mallory D, Malamut D, Eckrich R. IgA anaphylactic transfusion reactions. Transfus Med Rev 1995;9:1-8.
24. Popovsky MA, Chaplin HC Jr, Moore SB. Transfusion-related acute lung injury: a neglected, serious complication of hemotherapy. Transfusion 1992;32:589-92.
25. Chapman CE, Stainsby D, Jones H, et al. Ten years of hemovigilance reports of transfusion-related acute lung injury in the UK, and the impact of preferential use of male donor plasma. Transfusion 2009;49:440-452.
26. Win N, Massey E, Lucas G, et al. Ninety-six suspected transfusion related acute lung injury cases: investigation findings and clinical outcome. Hematology 2007;12:461-9.
27. Yomtovian R, Kline W, Press C, et al. Severe pulmonary hypersensitivity associated with passive transfusion of a neutrophil-specific antibody. Lancet 1984;1:244-6.
28. Levy GJ, Shabot MM, Hart ME, Mya WW, Goldfinger D. Transfusion-associated noncardiogenic pulmonary edema. Report of a case and a warning regarding treatment. Transfusion 1986;26:278-81.
29. Silliman CC, Ambruso DR, Boshkov LK. Transfusionrelated acute lung injury. Blood 2005;105:2266-73.
30. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991;324:667-74.
31. Shivdasani RA, Anderson KC. Transfusion-associated graft-versus-host disease: scratching the surface. Transfusion 1993;33:696-7.
32. Ohto H, Anderson KC. Survey of transfusionassociated graft-versus-host disease in immunocompetent recipients. Transfus Med Rev 1996;10:31-43.
33. Shivdasani RA, Haluska FG, Dock NL, et al. Brief report: graft-versus-host disease associated with transfusion of blood from unrelated HLA-homozygous donors. N Engl J Med 1993;328:766-70.
34. Kunstmann E, Bocker T, Roewer L, et al. Diagnosis of transfusion-associated graft-versus-host disease by genetic fingerprinting and polymerase chain reaction. Transfusion 1992;32:766-70.
35. Wang L, Juji T, Tokunaga K, et al. Brief report: polymorphic microsatellite markers for the diagnosis of graft-versus-host disease. N Engl J Med 1994;330: 398-401.
36. Sage D, Stanworth S, Turner D, Navarrete C. Diagnosis of transfusion-associated graft-vs.-host disease: the importance of short tandem repeat analysis. Transfus Med 2005;15:481-5.
37. Klein H. Standards for Blood Banks and Transfusion Services, 17th edn. American Association of Blood Banks, Bethesda, MD, 1996.
38. BCSH Blood Transfusion Task Force. Guidelines on gamma irradiation of blood components for the prevention of transfusion-associated graft-versus-host disease. Transfus Med 1996;6:261-71.
39. Williamson LM, Stainsby D, Jones H, et al. The impact of universal leukodepletion of the blood supply on hemovigilance reports of posttransfusion purpura and transfusion-associated graft-versus-host disease. Transfusion 2007;47:1455-67.
40. von dem Borne AE, van der Plas-van Dalen CM. Further observation on post-transfusion purpura (PTP). Br J Haematol 1985;61:374-5.
41. Gerstner JB, Smith MJ, Davis KD, Cimo PL, Aster RH. Posttransfusion purpura: therapeutic failure of PlAlnegative platelet transfusion. Am J Hematol 1979; 6:71-5.
42. Win N, Peterkin MA, Watson WH. The therapeutic value of HPA-1 a-negative platelet transfusion in post-transfusion purpura complicated by life-threatening haemorrhage. Vox Sang 1995;69: 138-9.
43. Shulman NR, Aster RH, Leitner A, Killer MC. Immunoreactions involving platelets. V. Posttransfusion purpura due to a complement-fixing antibody against a genetically controlled platelet antigen. A proposed mechanism for thrombocytopenia and its relevance in 'autoimmunity'. J Clin Invest 1961; 40:1597-620.
44. Kickler TS, Ness PM, Herman JH, Bell WR. Studies on the pathophysiology of posttransfusion purpura. Blood 1986;68:347-50.
45. Christie DJ, Pulkrabek S, Putnam JL, Slatkoff ML, Pischel KD. Posttransfusion purpura due to an alloantibody reactive with glycoprotein Ia/IIa (anti-HPA-5b). Blood 1991;77:2785-9.
46. Weisberg LJ, Linker CA. Prednisone therapy of posttransfusion purpura. Ann Intern Med 1984;100:76-7.
47. Cimo PL, Aster RH. Post-transfusion purpura: successful treatment by exchange transfusion. N Engl J Med 1972;287:290-2.
48. Becker T, Panzer S, Maas D, et al. High-dose intravenous immunoglobulin for post-transfusion purpura. Br J Haematol 1985;61:149-55.